Everolimus

ID: everolimus

Aliases: RAD001, Afinitor, rapalog

Type: compound

Route/form: oral prescription tablet or tablet for suspension

Status: approved

Evidence level: approved / labelled

Best data tier: approved label + human controlled/review

Support scope: human, review/regulatory

Source types: human_rct, label, safety_review, systematic_review

Linked sources: 4

Broad outcomes: Gut / immune / inflammation, Longevity / mitochondrial / redox, mTORC / autophagy / nutrient signaling

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• mTORC1 inhibition
• PI3K-AKT-mTOR pathway modulation
• immunosenescence trial signal at low dose

Optimization domains

• mTORC1
• mTOR
• autophagy
• immune aging
• cancer
• TSC
• safety

Research basis

• Everolimus/RAD001 is a clinically used rapalog with official label context and direct involvement in the human elderly immune-function mTOR trial.
• It helps separate rapamycin-like mTORC1 inhibition from sirolimus itself and from broader PI3K/mTOR programs such as RTB101.
• The approved oncology/TSC context makes the adverse-effect profile much more concrete than generic longevity discussion.

Limits, risks, and missing evidence

• Approved everolimus use is cancer/TSC/transplant-type medicine, not healthy-user anti-aging or performance optimization.
• Stomatitis, infection, pneumonitis, hyperglycemia, dyslipidemia, renal effects, cytopenias, and drug interactions are not minor wellness concerns.
• Short-term immune-function signals in older adults should not be generalized to chronic unmonitored mTOR inhibition.

Risk flags

• prescription only
• immunosuppression
• stomatitis
• pneumonitis
• hyperglycemia
• dyslipidemia
• drug interactions

Linked papers, labels, and reviews

1. DailyMed label: AFINITOR everolimus tablet and AFINITOR DISPERZ everolimus tablet for suspension
   label / dailymed_everolimus_label
   Official everolimus label; oral mTOR inhibitor with cancer/TSC indications and warnings including pneumonitis, infection, metabolic, renal, and stomatitis risks.
2. mTOR inhibition improves immune function in the elderly
   human_rct / pubmed_mtor_inhibition_elderly_immune_2014
   Randomized elderly-volunteer trial using RAD001/everolimus before influenza vaccination; central human evidence for low-dose rapalog immunosenescence discussions.
3. Stomatitis And Everolimus: A Review Of Current Literature On 8,201 Patients
   safety_review / pubmed_everolimus_stomatitis_review_2019
   Large safety review focused on stomatitis/mucocutaneous toxicity and broader mTOR-inhibitor adverse effects.
4. Everolimus therapy and side-effects: A systematic review and meta-analysis
   systematic_review / pubmed_everolimus_side_effects_meta_2021
   Systematic review/meta-analysis of everolimus adverse events; useful counterweight to longevity/immune-function extrapolations.